Köninger J, Greinacher A, Müller-Beissenhirtz W, Strosche H
Chirurgische Klinik, Bürgerhospital Stuttgart.
Unfallchirurg. 1995 Jan;98(1):49-51.
Recent studies have shown that low-molecular-weight heparins (LMWH) are not suitable for treating patients with heparin-associated thrombopenia (HAT) type 2, as they can cause the same complications as unfractionated heparin UFH. The case described ist that of concerns as female patient who died after developing HAT type 2 following LMWH given perioperatively to prevent thromboembolism. This case indicates again that LMWH can trigger HAT type 2 even if administered only once a day. For HAT to be successfully treated it is essential that the condition is diagnosed early enough by means of routine regular laboratory checks of the number of thrombocytes during any heparin treatment in order to detect the disease before clinical symptoms become apparent.
近期研究表明，低分子量肝素（LMWH）不适用于治疗2型肝素相关血小板减少症（HAT）患者，因为它们可能会引发与普通肝素（UFH）相同的并发症。本文描述了一例令人担忧的病例，一名女性患者在围手术期接受LMWH预防血栓栓塞后发生2型HAT并死亡。该病例再次表明，即使LMWH每天仅给药一次，也可能引发2型HAT。为了成功治疗HAT，在任何肝素治疗期间，通过对血小板数量进行常规定期实验室检查来尽早诊断病情至关重要，以便在临床症状出现之前发现该疾病。
